Sodium-glucose co-transporter-2 inhibition vs. dipeptidyl peptidase-4 inhibition in diabetic kidney transplant recipients: Single center experience

被引：0
|
作者：
Gheith, Osama [1 ]
AlOtaibi, Torki M. [1 ]
Mostafa, Ahmed Y. [1 ]
Shaker, Mohamed [1 ]
Khalid, Mahmoud [1 ]
Emam, Mohamed [1 ]
Mostafa, Mohammed [1 ]
Nagib, Ayman Maher [1 ]
Alserwy, Nabil [1 ]
Othman, Nashwa [1 ]
Dahab, Mohamed [1 ]
Nair, Prasad [1 ]
Denewar, Ahmed [1 ]
机构：
[1] Hamad Alessa OTC, Kuwait, Kuwait
来源：
TRANSPLANTATION | 2024年 / 108卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
441.3
引用
收藏
页码：368 / 368
页数：1
相关论文
共 50 条
  • [21] Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study
    Han, Seung Jin
    Ha, Kyoung Hwa
    Lee, Nami
    Kim, Dae Jung
    DIABETES OBESITY & METABOLISM, 2021, 23 (03): : 682 - 691
  • [22] Risk of Inflammatory Bowel Disease with Sodium Glucose Co-Transporter-2 Inhibitors Compared to Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes
    Dawwas, Ghadeer K.
    Smith, Steven M.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 38 - 38
  • [23] Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
    Alicic, Radica Z.
    Neumiller, Joshua J.
    Johnson, Emily J.
    Dieter, Brad
    Tuttle, Katherine R.
    DIABETES, 2019, 68 (02) : 248 - 257
  • [24] Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis
    Takahashi, Hirokazu
    Asakawa, Keiko
    Kosakai, Yoshinori
    Lee, Takumi
    Rokuda, Mitsuhiro
    DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 997 - 1007
  • [25] Changes in prescribing of sodium-glucose co-transporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors in Singapore
    Goh, Louise G. H.
    Sun, Jiandong
    Ng, Kwong
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 141 - 141
  • [26] Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes
    Kohsaka, Shun
    Takeda, Masayoshi
    Kidani, Yoko
    Yajima, Toshitaka
    DIABETES OBESITY & METABOLISM, 2021, 23 : 28 - 39
  • [27] COMBINED TREATMENT WITH ANTI-DIABETIC AGENTS; DIPEPTIDYL PEPTIDASE-4 INHIBITOR (DPP4-I) AND SODIUM-GLUCOSE CO-TRANSPORTER-2 INHIBITOR (SGLT2-I) SUPPRESSES PROGRESSION IN NASH RAT MODEL
    Namisaki, Tadashi
    Ozutsumi, Takahiro
    Kaji, Kosuke
    Shimozato, Naotaka
    Saikawa, Soichiro
    Takaya, Hiroaki
    Nakanishi, Keisuke
    Tsuji, Yuki
    Sawada, Yasuhiko
    Furukawa, Masanori
    Fujinaga, Yukihisa
    Kaya, Daisuke
    Kawaratani, Hideto
    Akahane, Takemi
    Yoshiji, Hitoshi
    HEPATOLOGY, 2019, 70 : 1290A - 1290A
  • [28] Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature
    Bonora, Benedetta Maria
    Avogaro, Angelo
    Fadini, Gian Paolo
    DIABETES OBESITY & METABOLISM, 2018, 20 (01): : 25 - 33
  • [29] Sodium-Glucose Co-Transporter 2 Inhibitors; Short-Term Outcome in Diabetic Kidney Transplant Recipients.
    Yagan, J.
    Mahmoud, T. S.
    Hasan, A.
    Gheith, O.
    El-Serwy, N.
    Rida, S.
    Mostafa, M.
    Shaker, M.
    Nair, P.
    Alotaibi, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 341 - 342
  • [30] Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
    Mahling, Moritz
    Schork, Anja
    Nadalin, Silvio
    Fritsche, Andreas
    Heyne, Nils
    Guthoff, Martina
    KIDNEY & BLOOD PRESSURE RESEARCH, 2019, 44 (05): : 984 - 992
12345